Ranibizumab in neovascular age-related macular degeneration

被引：18

作者：

Eng, Kenneth T. ^{[2
,3
,4
]}

Kertes, Peter J. ^{[1
,3
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada

[2] Hop Hotel Dieu, Kingston, ON, Canada

[3] Univ Toronto, Dept Ophthalmol & Visual Sci, Toronto, ON M5S 1A1, Canada

[4] Queens Univ, Dept Ophthalmol, Kingston, ON K7L 3N6, Canada

来源：

CLINICAL INTERVENTIONS IN AGING | 2006年 / 1卷 / 04期

关键词：

age-related macular degeneration; choroidal neovascularization; ranibizumab; bevacizumab;

D O I：

10.2147/ciia.2006.1.4.451

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.

引用

页码：451 / 466

页数：16

共 52 条

[31] Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment [J].

Maturi, Raj K. ;

Bleau, Laura A. ;

Wilson, Donald L. .

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :270-274

[32]

McColm J, 2004, MOL VIS, V10, P512

[33] Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration - Twelve-week results of an uncontrolled open-label clinical study [J].

Michels, S ;

Rosenfeld, PJ ;

Puliafito, CA ;

Marcus, EN ;

Venkatraman, AS .

OPHTHALMOLOGY, 2005, 112 (06) :1035-1047

[34] Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following lntravitreal administration [J].

Mordenti, J ;

Cuthbertson, RA ;

Ferrara, N ;

Thomsen, K ;

Berleau, L ;

Licko, V ;

Allen, PC ;

Valverde, CR ;

Meng, YG ;

Fei, DTW ;

Fourre, KM ;

Ryan, AM .

TOXICOLOGIC PATHOLOGY, 1999, 27 (05) :536-544

[35] Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration [J].

Penfold, PL ;

Wen, L ;

Madigan, MC ;

Gillies, MC ;

King, NJC ;

Provis, JM .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2000, 121 (03) :458-465

[36] Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey [J].

Reinke, MH ;

Canakis, C ;

Husain, D ;

Michaud, N ;

Flotte, TJ ;

Gragoudas, ES ;

Miller, JW .

OPHTHALMOLOGY, 1999, 106 (10) :1915-1923

[37]

Renno RZ, 2000, INVEST OPHTH VIS SCI, V41, P3963

[38]

Robinson CJ, 2001, J CELL SCI, V114, P853

[39] Ranibizumab for neovascular age-related macular degeneration [J].

Rosenfeld, Philip J. ;

Brown, David M. ;

Heier, Jeffrey S. ;

Boyer, David S. ;

Kaiser, Peter K. ;

Chung, Carol Y. ;

Kim, Robert Y. .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1419-1431

[40] Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration [J].

Rosenfeld, PJ ;

Schwartz, SD ;

Blumenkranz, MS ;

Miller, JW ;

Haller, JA ;

Reimann, JD ;

Greene, WL ;

Shams, N .

OPHTHALMOLOGY, 2005, 112 (06) :1048-1053

← 1 2 3 4 5 6 →